Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02961101Phase 1Recruiting

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Role: lead

NCT04697940Phase 1Active Not Recruiting

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Role: lead

NCT04026269Phase 1Unknown

Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen

Role: lead

NCT01799083Phase 1Unknown

Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas

Role: lead

NCT01828008Unknown

Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas

Role: lead

All 5 trials loaded